In this interview with Andrew Kleuss on Investors Hub, Vitaliy makes the case that concerns over Amazon’s entry into the pharmaceuticals business are probably overblown. To parse this problem, Vitaliy differentiates between pharmacies and drug distributors, and analyzes the extent to which Amazon can compete with both. While Amazon might place some pressure on pharmacies over time, he explains how drug distributors’ unique supply chains should remain robust against a competitive threat from Amazon.
Related Articles
Trump’s call for a bitcoin strategic reserve is a very bad idea – Ep 231
At the end of July, Donald Trump went full Bitcoin. He wants the US to become a “Bitcoin superpower”; he promised to build a Bitcoin strategic reserve. 📩 Join 89,000+ readers on my FREE weekly email newsletter: 📚 Get my...
Unpacking Buffett’s Investment Philosophy: A Personal Perspective – Ep 230
How does our investment approach stack up against Warren Buffett’s? Answering this question gives me a chance to dissect Buffett’s famous investment principles and compare them to our own strategy. 📩 Join 89,000+ readers on my FREE...
The Eclectic Value Investor – Ep 229
How do I describe myself as an investor? This question provides an opportunity to delve into what I mean by being an “eclectic value investor with a slight touch of dogmatism.” It’s a comprehensive look at our investment philosophy and approach....
The AI Revolution – Ep 228
The discussion of AI quickly falls into a domain bordering on Sci-Fi. My thoughts here are only marginally shaped by scientific facts. If you look at technological progress over the centuries through the lens of productivity, the improvement was tiny,...
0 comments